上海市人民政府办公厅今日印发《上海市全面深化药品医疗器械监管改革促进医药产业高质量发展的若 干措施》的通知，其中提到，强化标准引领。积极参与药品医疗器械国家标准制修订和国际标准协调。 发挥新型标准化技术组织作用，推进人工智能医疗器械、医用机器人、脑机接口、粒子治疗设备、创新 中医诊疗设备、细胞与基因治疗等前沿技术的标准化研究。持续开展中药饮片、中药配方颗粒及中医医 疗器械标准研究，依托国际标准化组织/中医药技术委员会（ISO/TC249）等国际标准化平台，制定中医 药国际标准。支持药品医疗器械生产过程数字化追溯等团体标准制订。 ...

维康药业公告，公司首次公开发行股票之募投项目"医药大健康产业园一期项目(中药饮片及中药提取、 研发中心、仓储中心)"已达到预定可使用状态并已结项，前述募投项目节余募集资金共计5539.2万元(包 含利息收入，具体金额以资金转出当日银行结算余额为准)，为了更好地提高募集资金使用效益，公司 拟将上述节余募集资金永久补充流动资金，用于公司日常经营和业务发展。 ...

Core Viewpoint - The article emphasizes the health risks associated with expired medications, highlighting misconceptions about their safety and efficacy, particularly regarding both Western and traditional Chinese medicines [1][2][3]. Group 1: Misconceptions about Expired Medications - There is a prevalent belief that expired medications are safe to consume if they have not visibly changed, which is incorrect [1]. - Some individuals think that Western medicines have expiration dates while traditional Chinese medicines do not, which is misleading [1][3]. Group 2: Health Risks of Expired Medications - Expired medications can not only lose their effectiveness but may also undergo chemical changes that produce harmful substances [2]. - For instance, expired antibiotics may lose their ability to combat infections, potentially worsening health conditions [2]. - Certain medications, like aspirin, can decompose into harmful compounds that may cause gastrointestinal issues [2]. Group 3: Regulations and Storage of Traditional Chinese Medicine - The National Medical Products Administration has mandated that traditional Chinese medicine products must display expiration dates starting August 1, 2025, to ensure safety and efficacy [3]. - Proper storage of traditional Chinese medicines is crucial, as improper conditions can lead to spoilage and loss of effectiveness [3][8]. Group 4: Importance of Proper Storage - Effective storage conditions are essential for maintaining the safety and efficacy of medications, with specific temperature and humidity requirements [7]. - Medications should be stored according to their instructions, and opened products should be used within a specified timeframe to avoid contamination [6][7]. Group 5: Recommendations for Home Medicine Management - Regularly cleaning out home medicine cabinets and disposing of expired or spoiled medications is advised [8]. - Traditional Chinese medicines should be categorized and stored appropriately to prevent moisture and pest damage [8].

本届展会汇集了覆盖全国等级医院、零售药店、医药电商、基层医疗终端等全渠道的专业资源与合作伙 伴，吸引了来自政府机构、行业组织、产业园区、医药工业及相关服务业等专业观众参观、洽谈。"专 区专展"的展出模式更是极大程度地凝聚目标观众，展会一大亮点即是创新设立了"高增长渠道专区"， 精准锚定基层医疗与医药新零售两大高潜力赛道，旨在为企业破解渠道拓展困局提供一个精准、高效、 系统化的解决方案。 展会同期举办超过30+场热点主题会议论坛，涵盖商业流通、市场营销、政策法规、中医药、国际化、 研发创新、零售、热点赛道等模块。贴近市场新机遇的10+场特备活动，包括高增长渠道系列活动、中 医药主题系列活动、首发经济系列活动等。在精心策划的一系列创新互动活动中，"新耀登场"新品首发 show作为展会倾力打造的年度新品首发阵地，为行业注入了创新活力。重磅会议与多彩活动成为焦 点，参与人员络绎不绝，彰显了中国医药健康产业的蓬勃活力。 11月19日至21日，第91届全国药品交易会（PHARMCHINA）、中医药博览会、中国药店采购供应博览 会携手2025中国国际健康营养博览会（NHNE）重磅亮相南京国际博览中心。 作为中国医药制剂与大 ...

Core Viewpoint - Yifeng Pharmacy has seen significant insider selling this year, with three executives and the controlling shareholder reducing their stakes, raising questions about the performance of the company's 2022 restricted stock incentive plan and whether executives have profited from it [1][2][3]. Group 1: Insider Selling - In 2025, Yifeng Pharmacy's controlling shareholder, Houxin Chuangtou, and its executives have completed share reduction plans, with a total of 24,248,200 shares sold, accounting for 2.00% of the total share capital [2]. - Executives including Gao Youcheng and Yan Jun have also sold shares, with prices ranging from 22 to 25 yuan [2][3]. - The upcoming share reductions by executives Wang Yonghui and Xiao Zaixiang involve a total of 213,900 shares [1]. Group 2: Performance of Incentive Plan - The shares sold by executives were obtained through the 2022 restricted stock incentive plan and capital reserve conversion [3][4]. - The 2022 incentive plan was deemed successful, meeting company performance assessment requirements [4][8]. - The performance targets for the incentive plan required a net profit increase of at least 20% in 2022 and 45% in 2023 compared to 2021 [5][6]. Group 3: Financial Performance - Yifeng Pharmacy's net profits from 2021 to 2024 were 888 million, 1.262 billion, 1.412 billion, and 1.529 billion yuan, showing growth rates of approximately 42.12%, 59.01%, and 72.18% respectively [7]. - Despite the growth in net profit, the company's revenue growth has slowed, with a reported revenue of 17.286 billion yuan in the first three quarters of 2025, a year-on-year increase of only 0.39% [8].

11月17日，佐力药业跌2.16%，成交额1.64亿元。两融数据显示，当日佐力药业获融资买入额2013.53万 元，融资偿还2075.26万元，融资净买入-61.72万元。截至11月17日，佐力药业融资融券余额合计5.70亿 元。 融资方面，佐力药业当日融资买入2013.53万元。当前融资余额5.68亿元，占流通市值的4.71%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，佐力药业11月17日融券偿还0.00股，融券卖出3200.00股，按当日收盘价计算，卖出金额5.51 万元；融券余量9.74万股，融券余额167.63万元，超过近一年90%分位水平，处于高位。 资料显示，浙江佐力药业股份有限公司位于浙江省德清县阜溪街道志远北路388号，成立日期2000年1月 28日，上市日期2011年2月22日，公司主营业务涉及药用真菌乌灵系列和百令片产品、中药饮片及中药 配方颗粒的研发、生产与销售。主营业务收入构成为：乌灵系列56.07%，中药饮片系列21.85%，其他 产品10.11%，百令系列7.08%，中药配方颗粒4.62%，其他(补充)0.26%。 截至9月30日，佐力药业股东户数4.14万，较上 ...

Core Viewpoint - The Anhui Provincial Drug Administration has introduced measures to enhance the regulation of pharmaceuticals and medical devices, aiming to promote high-quality development in the pharmaceutical industry [1][2]. Group 1: Reform Measures - The newly issued measures include 21 specific reform initiatives across five key areas, focusing on supporting drug and medical device research and innovation, as well as the development of traditional Chinese medicine [1]. - Anhui will strengthen tracking services for drug and medical device research, implementing a tailored approach for each company with comprehensive guidance throughout the process [1]. Group 2: Enhancing Approval Processes - The measures aim to improve the efficiency of drug and medical device review and approval processes by enhancing the capabilities of the review team and optimizing the approval workflow [2]. - A tracking service mechanism will be established for key parks, projects, and innovative products to facilitate faster market entry for urgently needed drugs and devices [2]. Group 3: Promoting Industry Compliance - The measures encourage the development of pharmaceutical industry clusters and support the establishment of high-standard specialty industrial parks in regions with existing advantages [2]. - There will be an emphasis on enhancing the regulatory quality of new pharmaceutical distribution models and fostering collaboration in innovative research and development [2].

中国发展网讯 记者明慧报道 11月15日上午，由中国当代医药杂志社和二十一世纪公益基金会主办，蒙 牛集团、扬子江药业集团、北京本草方源药业集团、百芝堂中医药集团、北京四方中药饮片有限公司等 单位协办，北京市大兴区卫生健康委员会、北京新融公益基金会等单位支持的第六届院士院长大会（简 称"两院论坛"）在北京市大兴区举行。中国中医药信息学会第四届理事会会长、国家中医药管理局原副 局长吴刚，中国科学院院士韩济生、陈润生、赵宇亮（线上），中国工程院院士蒋建东，第十三届全国 政协常委、国际核能院院士张勤，北京市大兴区委卫生健康工委书记、区卫生健康委主任牛祥君等来自 医药卫生界的行业领导、专家学者和来自全国各地的医疗机构负责人等320多位代表出席了15日上午举 行的开幕式。 开幕式由国家中医药管理局国际司原司长、中国医院协会副会长、中国中医科学院广安门医院原书记王 笑频主持，吴刚致辞。 在开幕式上，牛祥君在致辞中表示："今天我们有幸迎来医药健康领域的学术脊梁——各位院士，临床 实践一线的中坚力量——各位院长，以及深耕科研与产业赛道的专家、学者、企业家同仁。对大兴而 言，这既是一份至高荣誉，更是推动大兴卫生健康事业和医药健康 ...

Core Viewpoint - The company has obtained a pharmaceutical business license for its wholly-owned subsidiary, Shandong Weiming Tianan Pharmaceutical Co., Ltd., allowing it to operate in various pharmaceutical sectors [1] Group 1 - The license was issued by the Shandong Provincial Drug Administration [1] - The approved business scope includes traditional Chinese medicine pieces, Chinese patent medicines, chemical drugs, and biological products (excluding vaccines) [1] - The license also covers the operation of refrigerated and frozen pharmaceuticals [1]

Core Viewpoint - Zhaoli Pharmaceutical's stock has experienced a decline of 2.05% on November 17, with a current price of 17.23 CNY per share and a market capitalization of 12.085 billion CNY, despite a year-to-date increase of 16.67% [1] Financial Performance - For the period from January to September 2025, Zhaoli Pharmaceutical reported a revenue of 2.28 billion CNY, reflecting a year-on-year growth of 11.48%, and a net profit attributable to shareholders of 510 million CNY, which is a 21.00% increase compared to the previous year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.442 billion CNY, with 942 million CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 41,400, up by 7.31%, while the average number of circulating shares per person decreased by 6.82% to 14,562 shares [2] - Among the top ten circulating shareholders, the "Innovative Medicine" fund holds 6.8549 million shares, an increase of 280,700 shares, while the "Southern CSI 1000 ETF" holds 6.4172 million shares, a decrease of 58,800 shares [3] Stock Performance - Zhaoli Pharmaceutical's stock has seen a decline of 2.43% over the last five trading days, 6.92% over the last twenty days, and 13.29% over the last sixty days [1] - The stock's trading volume on November 17 was 58.7402 million CNY, with a turnover rate of 0.56% [1] Business Overview - Zhaoli Pharmaceutical, established on January 28, 2000, and listed on February 22, 2011, specializes in the research, production, and sales of medicinal fungi, traditional Chinese medicine pieces, and formula granules [1] - The company's main revenue sources include the Wuling series (56.07%), traditional Chinese medicine pieces (21.85%), and other products [1] Industry Classification - Zhaoli Pharmaceutical is classified under the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1] - The company is associated with various concept sectors, including value growth, cell therapy, precision medicine, cancer treatment, and innovative drugs [1]